Dose and administration
JARDIANCE® (empagliflozin) is simple to initiate at 10 mg dosing across all indications in adults.1
Once daily dosing, any time of day1 | 
Swallow whole with water, with or without food1 | 
No upper age limit*1 |
JARDIANCE® is not recommended in severe hepatic impairment, should not be used in breastfeeding or type 1 diabetes, and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. JARDIANCE® should be avoided in pregnancy. Always refer to the SmPC before prescribing.
*Caution should be exercised in patients for whom an empagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or patients aged 75 years and older.
Mechanism of action
Sodium-glucose cotransporter 2 (SGLT2) is highly expressed in the kidney.1 By blocking reuptake of glucose and sodium in the kidneys, SGLT2 inhibitors increase the excretion of both in the urine.1
SGLT2 inhibitors have multiple effects on metabolism and fluid balance in the Cardio-Renal-Metabolic (CRM) interconnected system.1
Glycosuria
... which lowers plasma glucose, therefore reduces glycated haemoglobin (HbA1c) and glucose toxicity2
... which causes a caloric loss, resulting in weight loss1,3 and reduction in fat mass1,4
Osmotic diuresis
… which reduces plasma volume, leading to reduction in blood pressure and cardiac preload1,5
Natriuresis
... which alters tubular-glomerular feedback and reduces glomerular hyperfiltration6
... which reduces arterial pressure,7 leading to an improvement in cardiac afterload5
JARDIANCE® (empagliflozin) is a reversible, highly potent and selective competitive inhibitor of SGLT2.1
In addition to glucose lowering, JARDIANCE® (empagliflozin) demonstrated secondary benefits of reduction in weight and blood pressure in clinical trials although it is not licensed for this.7
SGLT2 inhibitors: mechanism of action8
Learn more about JARDIANCE® for:
Type 2 diabetes (T2D)
Chronic kidney disease (CKD)
Symptomatic chronic heart failure (CHF)
Abbreviations
CHF: chronic heart failure; CKD: chronic kidney failure; CRM: cardio-renal-metabolic; CV: cardiovascular; eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin; LV: left ventricular; SGLT2i: sodium-glucose co-transporter-2 inhibitor; T2D: type 2 diabetes mellitus.
- JARDIANCE® (empagliflozin) Summary of Product Characteristics (SmPC). Available at: http://www.medicines.org.uk/emc/medicine/28973.
- Torimoto K et al. Diabetol Metab Syndr. 2017;9:60.
- Ferrannini G et al. Diabetes Care. 2015;38:1730–1735.
- Ridderstråle M et al. Lancet Diabetes Endocrinol. 2014;2:691–700.
- Garg V et al. Prog Cardiovasc Dis. 2019;62:349–357.
- Wanner C et al. N Engl J Med. 2016; 375:323–334.
- Häring HU, et al. Diabetes Care. 2014;37:1650–1659.
- Kalra S. Diabetes Ther. 2014 Dec;5:355-66.
PC-GB-110622 | December 2024
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.
- JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-109995 V4 | October 2025